Stefan Laufer
Affiliations: | Medicinal Chemistry | Eberhard Karls Universität Tübingen, Tübingen, Baden-Württemberg, Germany |
Google:
"Stefan Laufer"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Röhm S, Schröder M, Dwyer JE, et al. (2020) Selective targeting of the αC and DFG-out pocket in p38 MAPK. European Journal of Medicinal Chemistry. 208: 112721 |
| Laufkötter O, Laufer S, Bajorath J. (2020) Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome. Data in Brief. 32: 106189 |
| Laufkötter O, Laufer S, Bajorath J. (2020) Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. European Journal of Medicinal Chemistry. 204: 112641 |
| Laufer S, Briner K, Bajorath J, et al. (2020) New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. Journal of Medicinal Chemistry |
| Scior T, Abdallah HH, Salvador-Atonal K, et al. (2020) Dapsone is not a Pharmacodynamic Lead Compound for its Aryl Derivatives. Current Computer-Aided Drug Design. 16: 327-339 |
| Cianni L, Lemke C, Gilberg E, et al. (2020) Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents. Plos Neglected Tropical Diseases. 14: e0007755 |
| González-Medina M, Miljković F, Haase GS, et al. (2019) Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. European Journal of Medicinal Chemistry. 187: 112004 |
| Röhm S, Berger BT, Schröder M, et al. (2019) A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors. Journal of Medicinal Chemistry |
| Guenthoer P, Fuchs K, Reischl G, et al. (2019) Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis. Inflammopharmacology |
| do Amaral DN, Lategahn J, Fokoue HH, et al. (2019) A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports. 9: 14 |